Amendment: SEC Form SC 13G/A filed by 4D Molecular Therapeutics Inc.
$FDMT
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 9/23/2024 | Overweight → Neutral | Cantor Fitzgerald | |
| 4/15/2024 | $45.00 | Overweight | Barclays |
| 4/15/2024 | $459.00 | Overweight | Barclays |
| 2/7/2024 | $81.00 | Buy | Goldman |
| 10/26/2023 | $25.00 | Outperform | RBC Capital Mkts |
| 10/24/2023 | $32.00 | Overweight | Cantor Fitzgerald |
| 10/18/2023 | $24.00 | Market Perform → Outperform | Leerink Partners |
| 7/5/2023 | $30.00 | Buy | Chardan Capital Markets |
SC 13G/A - 4D Molecular Therapeutics, Inc. (0001650648) (Subject)
SC 13G/A - 4D Molecular Therapeutics, Inc. (0001650648) (Subject)
SC 13G - 4D Molecular Therapeutics, Inc. (0001650648) (Subject)
4DMT acquires all world-wide rights to short-form human complement factor H (sCFH) from Aevitas Therapeutics, Inc.; technology invented at University of PennsylvaniaAnnounces sCFH as payload for 4D-175 lead product candidate for geographic atrophy (GA); sCFH extensively characterized in 3 genetic mouse models and in non-human primates (NHP)CFH variants with reduced complement inhibitory function are a well-validated genetic risk factor for GA secondary to age-related macular degeneration (AMD), with approximately 75% of AMD patients carrying a high-risk variant of CFH; utilizing a precision medicine approach, this population represents a potential target population for 4D-175Continues expans
All three patients with 12 months of follow-up demonstrated improvement in multiple FDA-recommended cardiac endpoints at relatively low dose of 1E13 vg/kgCardiac biopsy demonstrated selective and widespread transgene expression within ~50% of cardiomyocytes Engaging with FDA to lift clinical hold and resume enrollment with updated exclusion criteria and highly effective rituximab/sirolimus immunosuppressive regimen to reduce risk of atypical hemolytic uremic syndrome ("aHUS")Otherwise, generally well-tolerated with no liver, heart, or dorsal root ganglia ("DRG") toxicity observedCompany to host live webcast today at 4:30 p.m. EST EMERYVILLE, Calif., Feb. 22, 2023 (GLOBE NEWSWIRE) -- 4D Mo
Cohort 1 patients (n=5) received a single intravitreal injection of 4D-150 (3E10 vg/eye); these patients were high need patients who in the 12 months preceding trial enrollment had a mean annualized anti-VEGF injection rate of ~11Following intravitreal 4D-150, Cohort 1 patients' annualized anti-VEGF injection rate was reduced by 96.7%80% of Cohort 1 patients had not received any supplemental aflibercept injections for up to ~10 months after 4D-150 dosingCohort 1 safety and tolerability of 4D-150 demonstrated to date, with no clinically significant intraocular inflammation or hypotony reportedConference call & webcast to be held Monday November 14, 2022 at 8:00 AM E.T. EMERYVILLE, Calif.
Dhaval Desai, PharmD, named as Chief Development Officer; will oversee late-stage Product Development, Medical Affairs, Scientific Communications, Regulatory and Quality operations; most recently SVP & Chief Development Officer at Iveric Bio where he led development and approval of IZERVAYChristopher Simms named as Chief Commercial Officer, effective September 25, 2024; will oversee Pre-commercial and Commercial organizations, pre-launch preparations and development; most recently SVP & Chief Commercial Officer at Iveric Bio where he led commercial strategy and execution for the launch of IZERVAYCarlos Quezada-Ruiz, M.D., FASRS, named as SVP, Therapeutic Area Head, Ophthalmology; will lead t
Poised for multiple meaningful catalysts in 2024 driven by strong clinical progress across large market programs in wet age-related macular degeneration (wet AMD), diabetic macular edema (DME) and cystic fibrosis (CF)Established next-generation AAV & CRISPR/Cas-based genetic medicines partnership for central nervous system (CNS) diseases with Arbor BiotechnologiesAnnounced organizational updates, including the appointment of UCSF Professor Noriyuki Kasahara (Nori), M.D., Ph.D. as Chief Scientific OfficerWell capitalized ending 2023 with $300 million in estimated cash, financial runway guidance unchanged and cash expected to be sufficient to fund operations into H1 2026 EMERYVILLE, Calif
EMERYVILLE, Calif., Sept. 12, 2023 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (NASDAQ:FDMT, 4DMT or the Company))), a clinical-stage biotherapeutics company harnessing the power of directed evolution for targeted genetic medicines, today announced the appointment of Uneek Mehra as Chief Financial & Business Officer of 4DMT. Mr. Mehra will succeed August J. Moretti, J.D., who is retiring, and has agreed to serve in an advisory capacity to support Mr. Mehra's transition. Mr. Mehra will lead 4DMT's finance, business development, and precommercial functions and will be a member of 4DMT's Executive Team, reporting to David Kirn, M.D., Co-founder and Chief Executive Officer of 4DMT. Mr. Mehr
4 - 4D Molecular Therapeutics, Inc. (0001650648) (Issuer)
4 - 4D Molecular Therapeutics, Inc. (0001650648) (Issuer)
4 - 4D Molecular Therapeutics, Inc. (0001650648) (Issuer)
Presented positive interim data for 4D-150 in wet age-related macular degeneration (wet AMD) from PRISM Phase 1/2 clinical trial highlighting robust and durable clinical activity across diverse patient populations and intraocular inflammation (IOI) profile numerically similar to approved anti-VEGF agents 4D-150 4FRONT Phase 3 program in wet AMD designed to maximize probability of success, continues to be on track with 4FRONT-1 trial initiation expected in Q1 2025 Continuing KOL engagement to expand awareness of the potential differentiated product profile of 4D-150Company product portfolio strategy and cash utilization updates, together with SPECTRA clinical trial program and interim data u
EMERYVILLE, Calif., Sept. 23, 2024 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (NASDAQ:FDMT, 4DMT or the Company))), a leading clinical-stage genetic medicines company focused on unlocking the full potential of genetic medicines to treat large market diseases, today announced a poster presentation at the 2024 North American Cystic Fibrosis Conference (NACFC) in Boston, Massachusetts on September 26-28, 2024. 2024 NACFC Poster Presentation Details: Title:Transgene expression and CFTR channel function in human bronchial epithelial cells following addition of CFTR modulators and 4D-710Poster Session:Poster 344Date/Time:Friday, September 27, 2024 (1:15 – 2:15 p.m. ET)Presenter:Melissa A.
4D-150 demonstrated robust and durable clinical activity across all wet age-related macular degeneration (wet AMD) patient populations based on longest available follow-up data In broad population (Phase 2b), 70% injection-free through 52 weeksIn severe population (Phase 1/2a), 83% overall reduction in annualized injections through 52 weeks 4D-150 continues to be safe and well tolerated with intraocular inflammation (IOI) profile numerically similar (2.8% transient 1+ vitreous cells) to approved anti-VEGF agents4FRONT Phase 3 program designed to maximize 4D-150's potential, including probabilities of clinical, regulatory and commercial success across global marketsCorporate webcast to be h
10-Q - 4D Molecular Therapeutics, Inc. (0001650648) (Filer)
8-K - 4D Molecular Therapeutics, Inc. (0001650648) (Filer)
8-K - 4D Molecular Therapeutics, Inc. (0001650648) (Filer)
Cantor Fitzgerald downgraded 4D Molecular Therapeutics from Overweight to Neutral
Barclays initiated coverage of 4D Molecular Therapeutics with a rating of Overweight and set a new price target of $45.00
Barclays initiated coverage of 4D Molecular Therapeutics with a rating of Overweight and set a new price target of $459.00
RBC Capital analyst Luca Issi reiterates 4D Molecular Therapeutics (NASDAQ:FDMT) with a Outperform and maintains $40 price target.
Shares of Domino’s Pizza, Inc. (NYSE:DPZ) fell sharply during Thursday's session after the company reported mixed quarterly results. The company reported second-quarter FY24 sales growth of 7.1% year-on-year to $1.097 billion, missing the analyst consensus estimate of $1.103 billion. The company is temporarily suspending its guidance metric of 1,100+ global net stores growth until the full effect of DPE's store opens and closures on international net store growth are known. Domino’s Pizza shares dipped 11.2% to $420.36 on Thursday. Here are some other stocks moving in today’s mid-day session. Gainers Onconetix, Inc. (NASDAQ:ONCO) climbed 97.6% to $0.2944. On July 15, Oncon
In the preceding three months, 5 analysts have released ratings for 4D Molecular Therapeutics (NASDAQ:FDMT), presenting a wide array of perspectives from bullish to bearish. Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months. Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 3 2 0 0 0 Last 30D 0 1 0 0 0 1M Ago 1 1 0 0 0 2M Ago 1 0 0 0 0 3M Ago 1 0 0 0 0 The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $38.0, a high estimate of $40.00, and a low estimate of $36.00. Highlighting a 10.8% decrease